Kim N, Cheng J, Jung I, Liang J, Shih YL, Huang WY, Kimura T, Lee VHF, Zeng ZC, Zhenggan R, et al. Stereotactic body radiation therapy vs. radiofrequency ablation in Asian patients with hepatocellular carcinoma. J Hepatol. 2020;73:121–9.

Article  CAS  PubMed  Google Scholar 

Heimbach JK, Kulik LM, Finn RS, Sirlin CB, Abecassis MM, Roberts LR, Zhu AX, Murad MH, Marrero JA. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018;67:358–80.

Article  PubMed  Google Scholar 

Cao S, Lyu T, Fan Z, Guan H, Song L, Tong X, Wang J, Zou Y. Long-term outcome of percutaneous radiofrequency ablation for periportal hepatocellular carcinoma: tumor recurrence or progression, survival and clinical significance. Cancer Imag. 2022;22:2.

Article  Google Scholar 

Teng W, Liu KW, Lin CC, Jeng WJ, Chen WT, Sheen IS, Lin CY, Lin SM. Insufficient ablative margin determined by early computed tomography may predict the recurrence of hepatocellular carcinoma after radiofrequency ablation. Liver Cancer. 2015;4:26–38.

Article  PubMed  PubMed Central  Google Scholar 

Shi L, Wang J, Ding N, Zhang Y, Zhu Y, Dong S, Wang X, Peng C, Zhou C, Zhou L, et al. Inflammation induced by incomplete radiofrequency ablation accelerates tumor progression and hinders PD-1 immunotherapy. Nat Commun. 2019;10:5421.

Article  PubMed  PubMed Central  Google Scholar 

Qi X, Yang M, Ma L, Sauer M, Avella D, Kaifi JT, Bryan J, Cheng K, Staveley-O’Carroll KF, Kimchi ET, Li G. Synergizing sunitinib and radiofrequency ablation to treat hepatocellular cancer by triggering the antitumor immune response. J Immunother Cancer. 2020. https://doi.org/10.1136/jitc-2020-001038.

Article  PubMed  PubMed Central  Google Scholar 

Sun H, Meng Q, Shi C, Yang H, Li X, Wu S, Familiari G, Relucenti M, Aschner M, Wang X, Chen R. Hypoxia-inducible exosomes facilitate liver-tropic premetastatic niche in colorectal cancer. Hepatology. 2021;74:2633–51.

Article  CAS  PubMed  Google Scholar 

Shi L, Chen L, Wu C, Zhu Y, Xu B, Zheng X, Sun M, Wen W, Dai X, Yang M, et al. PD-1 blockade boosts radiofrequency ablation-elicited adaptive immune responses against tumor. Clin Cancer Res. 2016;22:1173–84.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zerbini A, Pilli M, Penna A, Pelosi G, Schianchi C, Molinari A, Schivazappa S, Zibera C, Fagnoni FF, Ferrari C, Missale G. Radiofrequency thermal ablation of hepatocellular carcinoma liver nodules can activate and enhance tumor-specific T-cell responses. Cancer Res. 2006;66:1139–46.

Article  CAS  PubMed  Google Scholar 

Wang Y, Xiang Y, Xin VW, Wang X-W, Peng X-C, Liu X-Q, Wang D, Li N, Cheng J-T, Lyv Y-N, et al. Dendritic cell biology and its role in tumor immunotherapy. J Hematol Oncol. 2020;13:107.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sceneay J, Goreczny GJ, Wilson K, Morrow S, DeCristo MJ, Ubellacker JM, Qin Y, Laszewski T, Stover DG, Barrera V, et al. Interferon signaling is diminished with age and is associated with immune checkpoint blockade efficacy in triple-negative breast cancer. Cancer Discov. 2019;9:1208–27.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yu R, Zhu B, Chen D. Type I interferon-mediated tumor immunity and its role in immunotherapy. Cell Mol Life Sci. 2022;79:191.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gu Y, Fang Y, Wu X, Xu T, Hu T, Xu Y, Ma P, Wang Q, Shu Y. The emerging roles of SUMOylation in the tumor microenvironment and therapeutic implications. Exp Hematol Oncol. 2023;12:58.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hu Z, Teng XL, Zhang T, Yu X, Ding R, Yi J, Deng L, Wang Z, Zou Q. SENP3 senses oxidative stress to facilitate STING-dependent dendritic cell antitumor function. Mol Cell. 2021;81:940-952.e945.

Article  CAS  PubMed  Google Scholar 

Kumar S, Schoonderwoerd MJA, Kroonen JS, de Graaf IJ, Sluijter M, Ruano D, González-Prieto R, Verlaan-de Vries M, Rip J, Arens R, et al. Targeting pancreatic cancer by TAK-981: a SUMOylation inhibitor that activates the immune system and blocks cancer cell cycle progression in a preclinical model. Gut. 2022;71:2266–83.

Article  CAS  PubMed  Google Scholar 

Lightcap ES, Yu P, Grossman S, Song K, Khattar M, Xega K, He X, Gavin JM, Imaichi H, Garnsey JJ, et al. A small-molecule SUMOylation inhibitor activates antitumor immune responses and potentiates immune therapies in preclinical models. Sci Transl Med. 2021. https://doi.org/10.1126/scitranslmed.aba7791.

Article  PubMed  PubMed Central  Google Scholar 

Langston SP, Grossman S, England D, Afroze R, Bence N, Bowman D, Bump N, Chau R, Chuang BC, Claiborne C, et al. Discovery of TAK-981, a first-in-class inhibitor of SUMO-activating enzyme for the treatment of cancer. J Med Chem. 2021;64:2501–20.

Article  CAS  PubMed  Google Scholar 

Nacerddine K, Lehembre F, Bhaumik M, Artus J, Cohen-Tannoudji M, Babinet C, Pandolfi PP, Dejean A. The SUMO pathway is essential for nuclear integrity and chromosome segregation in mice. Dev Cell. 2005;9:769–79.

Article  CAS  PubMed  Google Scholar 

Wang L, Wansleeben C, Zhao S, Miao P, Paschen W, Yang W. SUMO2 is essential while SUMO3 is dispensable for mouse embryonic development. EMBO Rep. 2014;15:878–85.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kroonen JS, Vertegaal ACO. Targeting SUMO signaling to wrestle cancer. Trend Cancer. 2021;7:496–510.

Article  CAS  Google Scholar 

Houlton J, Cash H, Xu H, Swiecicki PL, Casper KA, Chinn SB, Clayburgh DR, Li RJ, Christian RJ, Halfpenny A, et al. Abstract CT139: intratumoral (IT) microdosing of the investigational SUMOylation inhibitor TAK-981 in a phase 0 CIVO trial demonstrates the reactivation of type I interferon (IFN1) signaling in head and neck squamous cell carcinoma (HNSCC). Cancer Res. 2022. https://doi.org/10.1158/1538-7445.AM2022-CT139.

Article  Google Scholar 

Houlton J, Clayburgh D, Li R, et al569 A CIVO intratumor microdose Phase 0 Trial of subasumstat (TAK-981) in combination with cetuximab or avelumab reveals Type 1 Interferon induction and immune activation in head and neck cancer patientsJournal for ImmunoTherapy of Cancer 2022;10. https://doi.org/10.1136/jitc-2022-SITC2022.0569.

Muñoz NM, Williams M, Dixon K, Dupuis C, McWatters A, Avritscher R, Manrique SZ, McHugh K, Murthy R, Tam A, et al. Influence of injection technique, drug formulation and tumor microenvironment on intratumoral immunotherapy delivery and efficacy. J Immunother Cancer. 2021. https://doi.org/10.1136/jitc-2020-001800.

Article  PubMed  PubMed Central  Google Scholar 

Mikhail AS, Morhard R, Mauda-Havakuk M, Kassin M, Arrichiello A, Wood BJ. Hydrogel drug delivery systems for minimally invasive local immunotherapy of cancer. Adv Drug Deliv Rev. 2023;202: 115083.

Article  CAS  PubMed  Google Scholar 

Wang M, Hu D, Yang Y, Shi K, Li J, Liu Q, Li Y, Li R, Pan M, Mo D, et al. Enhanced chemo-immunotherapy strategy utilizing injectable thermosensitive hydrogel for the treatment of diffuse peritoneal metastasis in advanced colorectal cancer. Adv Sci. 2023;10: e2303819.

Article  Google Scholar 

Tang Q, Lim T, Shen LY, Zheng G, Wei XJ, Zhang CQ, Zhu ZZ. Well-dispersed platelet lysate entrapped nanoparticles incorporate with injectable PDLLA-PEG-PDLLA triblock for preferable cartilage engineering application. Biomaterials. 2021;268: 120605.

Article  CAS  PubMed  Google Scholar 

Mellati A, Hasanzadeh E, Gholipourmalekabadi M, Enderami SE. Injectable nanocomposite hydrogels as an emerging platform for biomedical applications: a review. Mater Sci Eng C Mater Biol Appl. 2021;131: 112489.

Spada A, Emami J, Tuszynski JA, Lavasanifar A. The uniqueness of albumin as a carrier in nanodrug delivery. Mol Pharm. 2021;18:1862–94.

Article  CAS  PubMed  Google Scholar 

Kwon J, Bakhoum SF. The cytosolic DNA-sensing cGAS-STING pathway in cancer. Cancer Discov. 2020;10:26–39.

Article  CAS  PubMed  Google Scholar 

Chen Y. A new immuno-oncology target—SUMOylation. Trend Cancer. 2023;9:606–8.

Article  CAS